M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Docetaxel
Drug: Capecitabine

First Posted Date: 2002-11-27

Last Posted Date: 2011-08-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 603

Registration Number: NCT00050167

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

Phase 1

Completed

Conditions: Lymphoma
Leukemia

Interventions: Drug: Zevalin Radioimmunotherapy
Drug: Rituximab
Drug: Fludarabine
Drug: Cyclophosphamide
Procedure: Allogeneic Stem Cell Transplantation

First Posted Date: 2002-11-08

Last Posted Date: 2013-06-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 70

Registration Number: NCT00048737

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Therapy of Early Chronic Phase CML With Gleevec

Phase 2

Completed

Conditions: Leukemia, Myeloid, Chronic-Phase

Interventions: Drug: Gleevec

First Posted Date: 2002-11-06

Last Posted Date: 2016-01-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00048672

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes

Phase 1

Terminated

Conditions: Leukemia, Myelocytic, Acute

Interventions: Procedure: Apheresis
Biological: Stem Cell Transplant

First Posted Date: 2002-10-25

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00048100

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: ZD1839
Drug: Docetaxel

First Posted Date: 2002-10-25

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00048087

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients With Locally Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Bevacizumab
Drug: Capecitabine
Radiation: Radiotherapy

First Posted Date: 2002-10-16

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 48

Registration Number: NCT00047710

Locations: 🇺🇸
University of Texas MDAnderson Cancer Center, Houston, Texas, United States

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Lonafarnib (SCH66336)
Drug: Imatinib Mesylate (Gleevec)

First Posted Date: 2002-10-09

Last Posted Date: 2018-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00047502

Locations: 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States

Study of ABT-751 in Patients With Refractory Hematologic Malignancies

Phase 1

Completed

Conditions: Hematological Malignancies

First Posted Date: 2002-10-09

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 32

Registration Number: NCT00047489

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Study of Gelonin Purging of Autologous Stem Cells for Transplantation

Phase 1

Terminated

Conditions: Myelodysplastic Syndrome
Acute Myelogenous Leukemia

Interventions: Procedure: Gelonin
Drug: Busulfan
Drug: Fludarabine

First Posted Date: 2002-08-15

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00043810

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: Avastin
Drug: Tarceva

First Posted Date: 2002-08-15

Last Posted Date: 2018-11-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 41

Registration Number: NCT00043823

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy